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Abstract - Improving oral bioavailability of drugs those given as solid dosage forms remains a challenge for the formulation
scientists due to solubility problems. The dissolution rate could be the rate-limiting process in the absorption of a drug from a solid
dosage form of relatively insoluble drugs. Therefore increase in dissolution of poorly soluble drugs by solid dispersion technique
presents a challenge to the formulation scientists. Solid dispersion techniques have attracted considerable interest of improving the
dissolution rate of highly lipophilic drugs thereby improving their bioavailability by reducing drug particle size, improving
wettability and forming amorphous particles. The term solid dispersion refers to a group of solid products consisting of at least two
different components, generally a hydrophilic inert carrier or matrix and a hydrophobic drug. This article reviews historical
background of solid dispersion technology, limitations, classification, and various preparation techniques with its advantages and
disadvantages. This review also discusses the recent advances in the field of solid dispersion technology. Based on the existing
results and authors’ reflection, this review give rise to reasoning and suggested choices of carrier or matrix and solid dispersion
procedure.
Keywords - carrier; dissolution; matrix; poorly soluble drug; solid dispersion; solubility enhancement.

I.

molecules can be realized [10]. Therefore lots of efforts
have been made to increase dissolution of drug.
Methods available to improve dissolution include salt
formation, micronization and addition of solvent or
surface active agents. Solid dispersion (SD) is one of
such methods and involves a dispersion of one or more
active ingredients in an inert carrier or matrix in solid
state prepared by melting, dissolution in solvent or
melting-solvent method [2, 11]. The formulation of
drugs having low aqueous solubility using solid
dispersion technology has been an active area of
research since 1960 [12]. Among the various approaches
to improve solubility, the solid dispersion (SD)
technique has often proved to be the most successful in
improving the dissolution and bioavailability of poorly
soluble drugs because it is simple, economic, and
advantageous [13]. Solid dispersion means a group of
solid products consisting of at least two different
components, generally a hydrophilic inert carrier or
matrix and a hydrophobic drug. The carrier can be either
crystalline or amorphous in nature. Most commonly
used carriers for the preparation of SDs are different
grade of polyethylene glycols (PEGs) and
polyvinylpyrrolidone (PVPs), Gelucire 44/14, Labrasol,

INTRODUCTION

Oral bioavailability of drugs depends on its
solubility and/or dissolution rate, therefore major
problems associated with these drugs was its very low
solubility in biological fluids, which results into poor
bioavailability after oral administration [1-5]. A drug
with poor aqueous solubility will typically exhibit
dissolution rate limited absorption, and a drug with poor
membrane permeability will typically exhibit
permeation rate limited absorption [6]. Therefore,
pharmaceutical researchers’ focuses on two areas for
improving the oral bioavailability of drugs include: (i)
enhancing solubility and dissolution rate of poorly
water-soluble drugs and (ii) enhancing permeability of
poorly permeable drugs [7]. It has been estimated that
40% of new chemical entities currently being discovered
are poorly water soluble [8, 9]. Unfortunately, many of
these potential drugs are abandoned in the early stages
of development due to the solubility problems. It is
therefore important to realize the solubility problems of
these drugs and methods for overcoming the solubility
limitations are identified and applied commercially so
that potential therapeutic benefits of these active
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sugars, and urea [14-16]. The drug can be dispersed
molecularly, in amorphous particles (clusters) or in
crystalline particles [2]. The first drug whose rate and
extent of absorption was significantly enhanced using
the solid dispersion technique was sulfathiazole by
Sekiguchi and Obi [1]. This technique has been used by
many researchers/scientists for a wide variety of poorly
aqueous soluble drugs to enhance the solubility of the
drugs and hence bioavailability [13]. Literature reviews
on solid dispersion of past four decades suggests that
there is an increasing interest in using this approach [5].
Despite an active research interest, the number of
marketed products arising from this approach is really
disappointing. Only few commercial products were
marketed during the last four decades [1, 17, 18].
Several marketed and late stage drugs are designed for
improved solubility by solid dispersion are shown in
Table I [1, 17-19]. The goal of review is to highlight the
historical background of solid dispersion technology,
various preparation techniques with emphasis given to
their advantages and disadvantages, commonly used
carrier in the preparation of solid dispersions and the
recent advances in the field of solid dispersion
technology.

state shows higher drug release because no energy is
required to break up the crystal lattice during the
dissolution process [24, 25].
III. DISADVANTAGES OF SOLID DISPERSIONS
The major disadvantages of SDs are related to their
instability. Several systems have shown changes in
crystallinity and a decrease in dissolution rate on ageing.
By absorbing moisture, phase separation, crystal growth
or a change from metastable crystalline form to stable
form can take place which leads to the reduction of drug
solubility [26, 27]. Moisture and temperature have more
of deteriorating effect on solid dispersions than on
physical mixtures. Sometimes it is difficult to handle
because of tackiness [28].
IV. LIMITATIONS OF SOLID DISPERSIONS
Although a great research interest in solid
dispersion in the past four decades, the commercial
utilization is very limited. Problems of solid dispersion
involve (i) the physical and chemical stability of drugs
and vehicles, (ii) method of preparation, (iii)
reproducibility of its physicochemical properties, (iv)
formulation of solid dispersion into dosage forms, and
(v) scale-up of manufacturing processes [29].

II. ADVANTAGES OF SOLID DISPERSIONS
There are various reasons for the improvement of
solubility of poorly water-soluble drug using solid
dispersion technology. The reasons for solid dispersion
or advantages of solid dispersions are as follows:

V. CLASSIFICATION OF SOLID DISPERSIONS
SDs can be classified into simple eutectic mixtures,
solid
solutions,
and
physical
mixtures
of
microcrystalline drug dispersed in carriers [30]. A
simple eutectic mixture consists of two compounds that
are completely miscible in the liquid state but only to
very a limited extent in the solid state. A eutectic
mixture of a sparingly water soluble drug and a highly
water-soluble polymer or carrier may be regarded
thermodynamically as an intimately blended physical
mixture of its two crystalline component and these
components are assumed to crystallize simultaneously in
very small particulate sizes and thus increases the rate of
dissolution of a poorly water-soluble drug [31]. Solid
solution consists of a solid solute dissolved in a solid
solvent. In solid solution, particle size is reduced to
molecular level. Solid solutions of lower drug
concentrations generally give faster dissolution rate, and
the drug dissolution improves markedly with an increase
in molecular weight of a water-soluble polymer such as
PEG [31]. Solid solutions can be further classified into
three categories based on their miscibility into
continuous versus discontinuous solid solutions. As
shown in Figure 1, the solid molecules may be dispersed
in the solvent in three fashions these are: (i)
substitutional crystalline; (ii) interstitial crystalline; and
(iii) amorphous solid solutions [30].

Particles with reduced particle size : Molecular
dispersions, as solid dispersion, represent the last state
on particle size reduction, and after inert carrier or
matrix dissolution the drug is molecularly dispersed in
the dissolution medium [5]. A high surface area is
formed which results an increased dissolution rate and
further improved the bioavailability of the poorly watersoluble drug [20].
Particles with improved wettability : The solubility
enhancement of the drug is related to the drug
wettability improvement verified in solid dispersion
[21].
Particles with higher porosity : Particles in solid
dispersions have been found to have a higher degree of
porosity and the increase in porosity also depends on the
properties of the carrier. When polymers having linear
structure are utilized it produces larger and more porous
particle as compared with SDs that prepared with
reticular polymers. More porous nature of the particle
results higher dissolution rate [22, 23].
Drugs in amorphous state : Poorly water-soluble
crystalline drugs, when in the amorphous state tend to
have higher degree of solubility. Drug in its amorphous
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having its good solubility in different organic solvents.
Additional attractive features of such carriers include
improved compound wettability. This study clearly
shows that additions of various hydrophillic carriers like
urea, mannitol, PVP and PVP/VA-64 to aceclofenac
improves its dissolution rate. Further, all the solid
dispersions performed better than the corresponding
physical mixtures. The present study also showed that
urea, mannitol and PVP/VA-64 yielded solid dispersions
with a less improved dissolution rate than PVP as carrier
[32]. The melting point of a binary system is dependent
upon its composition, i.e., the weight fraction of drug
and the carrier present in the system. By proper
selection and control, the melting point of a binary
system may be much lower than the melting points of its
two components. Under such conditions, this melting
method can be used to prepare solid dispersions, even if
the pure drug may undergo decomposition at or near its
melting point [2].
The main advantages of this method are its
simplicity and economy. In addition melting under
vacuum or blanket of an inert gas such as nitrogen may
be used to prevent oxidation of drug or carrier material.
Although frequently applied, the fusion method has
serious limitations. Firstly, a major disadvantage is that
the method is only applied when the drug and matrix are
compatible and when they mix well at the heating
temperature. When the drug and matrix are incompatible
two liquid phases or suspension can be observed in the
heated mixture which results in an inhomogeneous solid
dispersion and this problem can be prevented by using
surfactants. Secondly, another problem may arise during
cooling when the drug-matrix miscibility changes. In
this case phase separation can occur. Indeed, it was
observed that when the mixture was slowly cooled,
crystalline drug occurred, whereas fast cooling yielded
amorphous solid dispersions. Thirdly, many substances,
either drugs or carriers, may decompose during the
fusion process at high temperatures [1, 33].

Fig. 1 : The classification of solid dispersions [30].
VI. PREPARATION OF SOLID DISPERSIONS
The fusion (melt), solvent evaporation, spray
drying, lyophilization (freeze drying), hot-melt
extrusion, electrostatic spinning method, coating on
sugar beads using fluidized bed-coating system,
supercritical fluid technology, are the methods reported
for the preparation of solid dispersions and these
methods are discussed below.
Fusion Method : The fusion method is sometimes
called melt method, which is correct only when the
starting materials are crystalline. Therefore, the more
general term “fusion method” is preferred. Fusion or
Melting method was first introduced by Sekiguchi et al.
in 1961 where the drug was melted in a carrier and after
cooling the dry mass obtained was pulverized and
sieved to obtain powder. They prepared the SDs of
Sulfathiazole in different carriers (e.g. ascorbic acid,
acetamide, nicotinamide, nicotinic acid, succinimide and
urea) by the formation of melt of different drug carrier
mixtures. Cooling of the drug-carrier melt was done on
ice bath with continuous stirring until the dry mass was
obtained [1]. Dua et al. in 2010, prepared solid
dispersions of aceclofenac with various hydrophilic
carriers (urea, mannitol, PVP and PVP/VA-64) in
different ratios such as 1:0.5, 1:1 and 1:2 by weight
basis using melting or fusion method) with an aim to
improve the extent and rate of dissolution. A particular
advantage of these carriers for the formation of SDs is

Traditional fusion method usually produces soft,
tacky materials with poor flow properties and
compressibility. Therefore, Gahoi et al., in 2011,
prepared lumefantrine (LMF) solid dispersion by a
novel solid dispersion technique ‘Dispersed Fusion’ to
improve dissolution rate with particular attention to
technological characteristics of granules. This novel
‘Dispersed Fusion’ technique involves spraying of
molten drug and hydrophilic inert carrier on diluent in
fluidized bed. They found that the drug particle size in
agglomerates was significantly reduced in ‘Dispersed
Fusion’ technique indicating strong impact of technique
[34].
Solvent Evaporation Method: Tachibana and
Nakamura were the two researchers who firstly applied
solvent evaporation method for the preparation of solid
dispersions. Drug (b-carotene) and carrier (PVP) were
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dissolved in a common solvent (chloroform) and solvent
was evaporated to form the solid mass [35]. Basically,
this solvent evaporation method involves two steps and
these are: (i) preparation of a solution containing both
matrix material or carrier and drug and (ii) the removal
of the solvent resulting in the formation of the solid
mass [10]. Nature of the solvent used and the rate and
temperature of evaporation of the solvent are the critical
factors which can affect the formed mass [36]. One of
the major advantages of this method is that thermal
decomposition of the drugs can be prevented as low
temperature is required for the evaporation of the
organic solvents. This method has several disadvantages
these are: (i) high cost of preparation, (ii) difficulty in
selecting a common solvent for both the drug and carrier
and complete solvent removal from the product can be a
lengthy process, and (iii) crystal forms are difficult to
reproduce [2, 37]. Many researchers studied solid
dispersion of valdecoxib [38], carbamazepine [39],
fexofenadine hydrochloride [40], and glibenclamide
[41] using solvent evaporation method. These findings
suggest that this method can be employed successfully
for the improvement and stability of SDs of poorly
water soluble drugs. Manimaran et al., in 2010, prepared
the solid dispersion of glibenclamide by the solvent
evaporation method using PVP, PEG6000 and
Poloxamer as hydrophilic carrier. In this study, they
observed that the solid dispersion prepared by using
various hydrophilic carriers enhanced the solubility of
glibenclamide to a varying degree. All SDs showed
increased dissolution rate as compared to pure
glibenclamide and PVP was found better than PEG and
Poloxamer [41].

oil). They concluded that SDs of the purely watersoluble drug etoricoxib was successfully prepared by
spray drying using lipid carriers [44]. Solid dispersion
using polyglycolized glycerides creates some problem
as already discussed above and this can be solved by
using silicon dioxide as an adsorbent. Due to presence
of surface silanol groups, silicon dioxide is able to form
hydrogen bond with drug molecule leading to the
increase in wettability and consequently enhanced
dissolution rate. SD of glibenclamide with Geluride was
successfully prepared using silicon dioxide as an
adsorbent by spray drying technique with enhanced
dissolution rate [45]. Al-Obaidi et al., in 2009, prepared
solid dispersions of griseofulvin by using spray drying
technology. Spray dried dispersions of griseofulvin
(GF),
poly[N-(2-hydroxypropyl)methacrylate]
(PHPMA) and polyvinylpyrrolidone (PVP) were
prepared from acetone and water. The glass transition
temperature for the ternary solid dispersion (GF,
PHPMA, and PVP) shifted from 83°C (acetone/water)
to 103°C for the acetone/methanol system. They found
that the SDs that was prepared using lower
concentrations of drug and polymers in solutions
resulted in the formation of particles that display a lower
relaxation rate. Their result also supports the hypothesis
that the polymer conformation may significantly change
the properties of the solid dispersion [46].
Lyophilization (freeze drying) : An important
advantage of freeze drying is that the drug is subjected
to minimal thermal stress during the formation of the
SDs. However, the most important advantage is that the
risk of phase separation is minimized as soon as the
solution is vitrified [47]. Singh et al., in 2011, dissolved
some selected solid dispersions in a minimum amount of
cyclohexanol. Then this solution was rapidly solidified
by transferring small portions with a Pasteur pipette
onto the inner surface of a cold flask rotating in a -50°C
methanol bath. After achieving a certain layer thickness,
the flask was attached to the vacuum adaptor of the
lyophilizer. The solvent was then sublimed under a
pressure of 8-10mmHg and condensed onto a -75°C
condenser. When the solvent was completely removed,
they found that the nature of the powder residue was
porous, light and fluffy mass [48]. Lokamatha et al., in
2011, prepared SDs of nevirapine (NVP) with the
objective of dissolution enhancement by kneading and
freeze drying technique using a novel carrier of low
molecular weight dextran (DEX) at varied
concentrations of drug:carrier (3:1 and 1:1w/w). They
first dispersed NVP and DEX in water, and then the
whole solution is stirred for 3 h. The solution is then
frozen overnight and then lyophilized over a period of
24 h using a freeze drier. Then the dried powder was
sieved through #120 and stored in dessicator. They
found that SDs of NVP: DEX, prepared by freeze drying
method exhibited a higher release rate than prepared by
kneading method [49].

Spray Drying : Spray drying method consists of
dissolving or suspending the drug and polymer in a
common solvent or solvent mixture and then drying it
into a stream of heated air flow to remove the solvent
[23]. Due to the large surface area of the droplets, the
solvent rapidly evaporates and solid dispersion is
formed within seconds, which may be fast enough to
phase separation. Spray drying usually yields drugs in
the amorphous state, but sometimes the drug may be
partially crystallized during processing [42, 43].
Polyglycolized glycerides (Gelucire) are available with
a range of properties depending on their hydrophilic
lipophilic balance (HLB) over the range of 1 to 18 and
melting point between 33o and 70°C. Preparation of SDs
by conventional spray drying with polyglycolized
glycerides has been problematic because a sticky and
tacky mass of polyglycolized glycerides is obtained.
Therefore, spray drying technique for polyglycolized
glycerides has been used with its combination highmelting lipids to solve this problem. Chauhan et al. in
2005, prepared solid dispersions of etoricoxib using
spray drying technique with lipid carriers, mainly
polyglycolized glycerides (Gelucire 50/13) and highmelting lipids, namely, Compritol (atomized glyceryl
dibehenate) or Sterotex K NF (hydrogenated cottonseed
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Hot-melt extrusion : This technology was first utilized
predominantly in the plastic industry and to lesser extent
in the food industry since 1930’s. Many advantages of
hot melt extrusion over conventional solid dosage form
manufacturing picked the interest of pharmaceutical
industry and researchers for the useful technology to
prepare novel drug delivery system [50]. This technique
employs the uses of extruders which consists of
conveying system, for transportation and mixing of
materials, and die system, which shapes the melt into
required shape like pellets, granules, or powder [51]. In
this method solvents are not used therefore, it is
environmentally friendly, economical and no residual
solvent in the final product. Advantage of hot melt
extrution technique over melting method is the use of
low temperature and short residence time which
prevents the drug-carrier mixture from thermal
degradation. Another advantage is that production is
continuous therefore fewer batches are required and
efficient scale-up from laboratory to large-scale
production [50, 52]. This method has several
disadvantages these are: (i) high shear forces may
produce high local temperature in the extruder therefore
it may create a problem for heat sensitive materials, (ii)
just like traditional fusion method, miscibility of drug
and carrier matrix can be a problem [53, 54]. 17βEstradiol hemihydrate (17β-E2) is a poorly watersoluble drug therefore, Hülsmann et al., in 2000,
prepared solid dispersion by melt extrusion technique
with an objective to overcome many of the
shortcomings of conventional methods. Different
compositions of excipients such as PEG 6000, PVP
(Kollidon® 30) or a vinylpyrrolidone-vinylacetatecopolymer (Kollidon® VA64) were used as polymers
and Sucroester® WE15 or Gelucire® 44/14 as additives
during melt extrusion. A 30-fold increase in dissolution
rate was obtained from a formulation containing 10%
17β-E2, 50% PVP and 40% Gelucire® 44/14. The SDs
was then processed into tablets and the improvement in
the dissolution behavior was also maintained with the
tablets [52]. Atorvastatin is a selective competitive
inhibitor of HMG CoA reductase and its absolute
bioavailability is 14% and therefore to increase its
solubility solid dispersion was prepared by using this
technique. Solid dispersion preliminary solubility
analysis was carried out for the selection of carriers and
solid dispersion was prepared with mannitol, PEG 4000
and PVP-K30. They found that the solid dispersions
obtained by this method were tacky enough [55].

electric field whereby the liquid is caused to produce
fibres. After being drawn from the liquid the fibres
harden, which may involve mere cooling, chemical
hardening or evaporation of solvent, and then hardened
fibres may be collected upon a suitably charged surface.
Tubular products comprising polyurethane fibres can be
prepared by this electrostatic spinning method. One
example of this type of tubular product is a vascular
prosthesis, particularly a synthetic blood vessel. Other
applications of this type of tubular products include the
use of different kinds of ducts, e.g. urinary, air or bile as
well as conduit through which for example a wire or
other device or structure may pass or lie [56]. The
electrostatic spinning method has a few applications in
pharmaceutical industry. In this method a drug-matrix
solution is pumped through an orifice and then subjected
to an electrical field to form fibres with a diameter of
micro- or nano-scale. This method is limited to a few
matrices because only a few high molecular weight
materials are fibre forming materials [57]. In this
method electrical forces are used to overcome the
surface tension of drug-polymer solution at air interface,
the fibres of submicron diameters are formed whose
diameter depends upon feeding rate, dielectric constant,
surface tension, electric field strength [18]. Verreck et
al., in 2003, assessed the application of water-soluble
polymer-based nanofibres prepared by electrostatic
spinning as a means of altering the dissolution rate of
the poorly water-soluble drug, itraconazole. Organic
solvent-based solutions of itraconazole/HPMC mixtures
were electrostatically spun at 16 and 24 kV. Then the
formed nanofibres were collected as a non-woven
fabric. Differential scanning calorimetry (DSC)
measurements found that the melting endotherm for
itraconazole was not present, suggesting the formation
of an amorphous solid dispersion or solution. They
concluded that the application of electrostatic spinning
to pharmaceutical applications resulted in dosage forms
with useful and controllable dissolution properties [58].
Verreck et al., in 2003, used electrostatic spinning
method
for
the
preparation
of
drug-laden
nonbiodegradable nanofibre for potential use in topical
drug administration and wound healing. Itraconazole
and ketanserin were selected as model compounds while
segmented polyurethane (PU) was selected as the
nonbiodegradable polymer. For both itraconazole and
ketanserin, an amorphous nanodispersion with PU was
obtained when the drug/polymer solutions were
electrospun from dimethylformide (DMF) and
dimethylacetamide (DMAc), respectively [59].

Some examples of pharmaceutically approved
polymeric materials which are used in hot-melt
extrusion include vinyl polymers (polyvinylpyrrolidone
(PVP), PVP-vinyl acetate (PVP-VA)), polyethylene
oxide (PEO), Eudragit® (acrylates), Polyethylene glycol
(PEG) and cellulose derivatives [50].

Coating on sugar beads using fluidized bed-coating
system : This method involves a fluidized bed-coating
system, wherein a drug-carrier solution is sprayed onto
the granular surface of excipients or sugar spheres to
produce either granule ready for tableting or drug-coated
pellets for encapsulation in one step. The method can be
applied for both controlled- and immediate-release solid
dispersions [29]. Itraconazole (Sporanox oral capsules,

Electrostatic Spinning Method : Electrostatic spinning
method involves the introduction of a liquid into an
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useful for the formulation of solid dosage forms [65].
Liu et al., in 2007, investigated the possibility of
preparing solid dispersions of the poorly soluble
budesonide by supercritical fluid (SCF) technique, using
poly (ethylene oxide) (PEO) as a hydrophilic carrier
using supercritical carbon dioxide (SC-CO2) as the
processing medium. They found that the enhanced
dissolution rates of budesonide were observed from
SCF-treated budesonide-PEO mixtures. The amorphous
characteristic of the budesonide, the better mixing of
drug and PEO powders in the presence of SC-CO2,
together with the improved wettability of the drug in
PEO, produced a remarkable enhancement of the in
vitro drug dissolution rate [66].

Janssen Pharmaceutica, Titusville, NJ) coated on sugar
sphere, is made by layering onto sugar beads a solution
of a drug and hydroxypropylmethylcellulose (HMPC) in
a mixture of suitable solvent system comprises a
mixture of methylenechloride and preferably ethanol
which may be denatured with butanone. As HPMC does
not dissolve completely in methylenechloride, at least
10% alcohol has to be added. A solid solution of drug in
HPMC is produced upon coating and controlled drying
of coated beads is done in a closed Wurster apparatus
[60].
Supercritical Fluid Technology : Supercritical fluid
(SCF) technology offers tremendous potential and the
low operating conditions (temperature and pressure)
make the method more attractive for pharmaceutical
research. In the pharmaceutical field, the supercritical
fluid technology was industrially applied in the early
1980’s. A supercritical fluid exists as a single phase
above its critical temperature and pressure [61]. The
most commonly used supercritical fluids for a variety of
applications include supercritical fluid carbon dioxide,
nitrous oxide, water, methanol, ethanol, ethane, propane,
n-hexane and ammonia [62]. Carbon dioxide is one of
the most commonly used SCFs because of its low
critical temperature (Tc = 31.1°C) and pressure (Pc =
73.8 bar). Apart from being nontoxic, nonflammable,
and inexpensive, the low critical temperature of CO2
makes it attractive for processing heat-labile molecules
[29]. This technique consists of dissolving the drug and
the inert carrier in a common solvent that is introduced
into a particle formation vessel through a nozzle,
simultaneously with CO2. When the solution is sprayed,
the solvent is rapidly extracted by the SCF, resulting in
the precipitation of solid dispersion particles on the
walls and bottom of the vessel [23]. This SCF
technology provides a novel alternative method of
preparation of small particles with higher surface area,
free flowing property, and a very low content of residual
organic solvent and this technology also avoids most of
the drawbacks of the traditional methods [29, 63]. A
variety of supercritical carbon dioxide techniques have
been developed with different working principles, such
as rapid expansion of supercritical solutions (RESS), gas
antisolvent precipitation (GAS), supercritical antisolvent
precipitation (SAS), precipitation with compressed fluid
antisolvent (PCA), solution enhanced dispersion by
supercritical fluids (SEDS), precipitation from gassaturated solutions (PGSS), etc [64]. Jun et al., in 2005,
prepared cefuroxime axetil (CA) solid dispersions with
HPMC 2910/PVP K-30 using solution enhanced
dispersion by supercritical fluids (SEDS) in an effort to
increase the dissolution rate of poorly water-soluble
drugs. FTIR analysis demonstrated that the presence of
intermolecular hydrogen bonds between CA and HPMC
2910/PVP K-30 in solid dispersions, result in the
formation of amorphous or non-crystalline CA. They
concluded that an amorphous or non-crystalline CA
solid dispersion prepared using SEDS could be very

VII. CONCLUSION
Since the concept of solid dispersion technology
was introduced in 1960s, great progresses have been
made in solid dispersion technology as solid dispersion
offers a variety of opportunities. A single solid
dispersion method cannot be universally accepted for a
variety of drug materials. In developing a new solid
dispersion system for a given drug, it is important to
understand the physicochemical properties of the drug
and carrier that best match the properties and find a
solid dispersion method. The preparation method and
the amount of the carrier also play a vital role in the
enhancement of drug dissolution rate. Most of the solid
dispersion work is in lab-scale setups; therefore the
manufacturing process requires enough knowledge to
scale up to the commercial scale.
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Table I : Several marketed and late stage drugs are designed for improved solubility by solid dispersion [1, 17-19].

Product/Substance

Dispersion Polymer or
Carrier

Technology used

Company

Gris-PEG® (Griseofulvin)

Polyethylene glycol

Melt process; exact
process unknown

Novartis

Sproramax capsules
(Itraconazole)

Hydroxypropylmethylcellulose
(HPMC)

Spray layering

Janseen
pharmaceutica

Cesamet®( Nabilone)

Providone

process unknown

Lilly

Kaletra (lopinavir and
ritonavir)

Polyvinylpyrolidone
(PVP)/polyvinyl acetate

Melt-extrusion

Abbott
Laboratories

Torcetrapiba

HPMC acetate succinate

Spray drying

Pfizer

Ibuprofen

Various

Melt-extrusion

Soliqs

Isoptin SRE-240 (Verapamil)

Various

Melt-extrusion

Soliqs

Rezulinb (Troglitazone)

PVP

Melt-extrusion

Pfizer

LCP-Tacro (Tracrolimus)

HPMC

Melt-granulation

Life Cycle Pharma

Intelence (Etravirine)

HPMC

Spray drying

Tibotec

Certican (Everolimus)

HPMC

Melt or Spray drying

Novartis

Afeditab (Nifedipine)

Poloxomer or PVP

Melt/absorb on carrier

Élan Corp.

a

Halted in phase III; b Withdrawn from market.
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